Stéphane Potvin

Stéphane Potvin, Ph. D.

Centre de recherche Fernand-Seguin
Hôpital Louis-H. Lafontaine
7331, rue Hochelaga
Montréal, Québec
H1N 3V2
Tél.: (514) 251-4015 poste 2851
Fax.: (514) 251-2617
Courriel : stephane.potvin@umontreal.ca  

---

Axe de recherche

• Signatures biologique, psychologique et sociale de la maladie mentale

Affiliation universitaire (poste ou fonction)

Chercheur adjoint
Département de psychiatrie, Université de Montréal

Prix et distinctions

Chercheur-boursier Junior 1 des Fonds de recherche en santé du Québec (2009-)

Intérêts de recherche

Toxicomanie et santé mentale
Douleur et santé mentale
Cannabis et cannabinoïdes endogènes
Antipsychotiques

Méthodologie

Psychopharmacology, psychophysics (pain), cognition, personality traits, magnetic resonance imaging, biomarkers (in collaboration) & meta-analysis

Enseignement

Séminaire de neuropsychopharmacologie (PST-6400)
• Co-responsable, à tous les 2 ans

Publications récentes

Stip, E., Zhornitsky, S., Potvin, S., & Tourjman, V. (2010). Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies. Progress in neuro-psychopharmacology & biological psychiatry. Pubmed

Zhornitsky, S., Rizkallah, E., Pampoulova, T., Chiasson, J. P., Stip, E., Rompre, P. P., Potvin, S., et al. (2010). Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. Journal of clinical psychopharmacology, 30(4), 417-424. Pubmed

Zhornitsky, S., Stip, E., Pampoulova, T., Rizkallah, E., Lipp, O., Bentaleb, L. A., Chiasson, J. P., Potvin, S., (2010). Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement disorders : official journal of the Movement Disorder Society. Pubmed

Potvin S, Normand E, Corbin JF, Marchand S. Pain inhibition is deficient in chronic widespread pain but normal in major depressive disorder. Journal of Clinical Psychiatry; Sous presse

Potvin S. Neuroimaging studies of substance abuse in schizophrenia. Current Psychiatry Reviews 2009; 5 (4): 250-60.

Potvin S, Blanchet P, Stip E. Substance abuse enhances extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophrenia Research 2009; 113 (2-3): 181-188.

Goffaux P, Barcellos-de-Souza J, Potvin S, Marchand S. Pain relief through expectation supersedes descending inhibititory deficits in fibromyalgia patients. Pain 2009; 145 (1-2): 18-23.

Larouche A, Potvin S, Normand E, Barcellos de Souza J, Grignon S, Marchand S. The DRD3 Ser9Gly polymorphism is related to thermal pain in chronic widespread pain patients and healthy volunteers. Journal of Pain 2009; 10 (9): 969-75.

De Souza JB, Goffaux P, Julien N, Potvin S, Charest J, Marchand S. Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Questionnaire: a preliminary study. Rheumatology International 2009; 29 (5): 509-15.

Potvin S, Grignon S, Marchand S. Human evidence of a supra-spinal modulating role of dopamine on pain perception. Synapse 2009; 63 (5): 390-402.

De Souza JB, Potvin S, Goffaux P, Charest J, Marchand S. The deficit in pain inhibition is more pronounced in chronic widespread pain patients with comorbid depressive symptoms. Clinical Journal of Pain 2009; 25 (2): 123-7.

Stip E, Mancini-Marië A, Fahim C, Bentaleb LA, Létourneau G, Potvin S. Decrease in basal ganglia grey matter density associated with atypical antipsychotic treatment. Schizophrenia Research 2008; 103 (1-3): 319-21.

Potvin S, Stip E, Lipp O, Tempier A, Bentaleb AL, Lalonde P, Goffaux P, Marchand S. Pain perception in schizophrenia: no changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization to thermal pain in schizophrenia. Journal Psychiatric Research 2008; 42: 1010-6.

Potvin S, Marchand S. Hypoalgesia in schizophrenia is independent of antipsychotic drugs: a meta-analysis. Pain 2008; 138 (1): 70-8.

Potvin S, Stip E, Kouassi E, Lipp O, Roy MA, Demers MF, Bouchard RH, Arista G, Piomelli D, Gendron A. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of Psychopharmacology 2008; 22 (3): 262-9.

Potvin S, Lipp O, Pampoulova T, Bentaleb AL, Lalonde P, Stip E. Working memory in patients with schizophrenia and substance use disorders. Cognitive Neuropsychiatry 2008; 13 (4): 357-66.

Redmond WJ, Goffaux P, Potvin S, Marchand S. Anti-hyperalgesic properties of nabilone – evidence of a sex-difference. Current Medical Research and Opinion 2008; 24 (4): 1017-24.

Potvin S, Joyal CC, Pelletier J, Stip E. Contradictory cognitive capacities in substance-abusing schizophrenia patients: a meta-analysis. Schizophrenia Research 2008; 100: 242-51.

Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alteration in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008; 63 (8): 801-8.

Potvin S, Stip E, Lipp O, Roy MA, Demers MF, Bouchard RH, Gendron A. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. American Journal of Drug and Alcohol Abuse 2008; 34 (1): 75-82.

Potvin S, Ben Amar M. Cannabis use increases the risk of psychotic outcomes (commentary). Evidence-Based Mental Health 2008; 11: 28.

Potvin S, Sepehry AA, Stip E. A meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Australian and New Journal of Psychiatry 2007; 41 (10): 792-9.

Potvin S, Mancini-Marïe A, Fahim C, Lévesque J, Karama S, Mensour B, Beauregard M, Rompré PP, Stip E. Increased striatal grey matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study. Psychiatry Research: Neuroimaging 2007; 154 (3): 275-9.

Potvin S, Mancini-Marië A, Fahim C, Mensour B, Stip E. A functional magnetic resonance imaging study of social emotion in schizophrenia patients with and without comorbid substance use disorder. Social Neuroscience 2007; 2 (2): 1-11.

Potvin S, Sepehry AA, Stip E. Comorbid substance-use in schizophrenia: the file drawer effect. Schizophrenia Research 2007; 90 (1-3): 351-2.

Sepehry AA, Potvin S, Élie R, Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. Journal of Clinical Psychiatry 2007; 68 (4): 604-10.

Ben Amar M, Potvin S. Cannabis and psychosis: what is the link? Journal of Psychoactive Drugs 2007; 39 (2): 131-42.

Levaux MN, Potvin S, Sepehry AA, Sablier J, Mendrek A, Stip E. Cognitive assessment in schizophrenia: promises and pitfalls of CANTAB. European Psychiatry 2007; 22 (2): 104-15.

Fahim C, Stip E, Mancini-Marië A, Potvin S, Malaspina D. Orbitofrontal dysfunctioning in a monozygotic twin discordant for post-partum affective psychosis: a fMRI case study. Bipolar Disorders 2007; 9 (5): 541-5.

Potvin S, Stip E. Schizophrénie et toxicomanie: l’héritage du psychiatre Jean-Yves Roy. Santé Mentale au Québec 2007; 31 (2): 177-88.

Légaré N, Potvin S, Mancini-Marië A, Barabé P, Lipp O, Bouchard RH, Stip E. Améliorer les symptômes et le tabagisme chez les personnes souffrant de schizophrénie : un manque d’effet synergique du médicament antipsychotique. Santé Mentale au Québec 2007; 31 (2): 165-74.

Potvin S, Grignon S. Dopamine et douleur: une revue de littérature. Douleur & Analgésie 2007; 20 (4): 246-56.

Arsenault P, Potvin S. Le traitement pharmacologique de la fibromyalgie: par où commencer? Douleur & Analgésie 2007 ; 20 (4): 227-33.

Potvin S, Stip E, Lipp O, Mancini-Marië A, Élie R, Roy MA, Rompré PP, Bouchard RH, Gendron A. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorder: an open-label trial. Current Medical Research Opinion 2006; 22 (7): 1277-85.

Mancini-Marië A, Potvin S, Fahim C, Mensour B, Beauregard M, Roy JY, Stip E. Neural correlates of the affect regulation model in schizophrenia patients with a substance use history: a functional magnetic resonance imaging study. Journal of Clinical Psychiatry 2006; 67 (3): 342-50.

Potvin S, Pampoulova T, Mancini-Marië A, Lipp O, Bouchard RH, Stip E. Increased extrapyramidal symptoms in schizophrenia patients with a comorbid substance use disorder. Journal of Neurology, Neurosurgery & Psychiatry 2006; 77 (6): 796-8.

Potvin S, Sepehry AA, Stip E. Negative symptoms in dual diagnosis schizophrenia: a meta-analysis. Psychological Medicine 2006; 36 (4): 431-40.

Potvin S, Briand C, Prouteau A, Bouchard RH, Lipp O, Lalonde P, Nicole L, Lesage A, Stip E. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain & Cognition 2005; 59: 38-42.

Mancini-Marië A, Fahim C, Potvin S, Stip E. Quetiapine: focus on emotional blunting in depersonalization disorder: a fMRI case report. European Psychiatry 2006; 21 (8): 574-7.

Tranulis C, Potvin S, Gourgue M, Leblanc G, Mancini-Marië A, Stip E. The paradox of quetiapine in obsessive-compulsive disorder. CNS Spectrums 2005; 10 (5): 356-61.

Potvin S, Stip E, Roy JY. Toxic psychoses as pharmacological models of schizophrenia. Current Psychiatry Reviews 2005; 1 (1): 23-32.

Potvin S, Stip E, Roy JY. The effect of quetiapine on cannabis use in eight psychosis patients with drug dependency. Canadian Journal of Psychiatry 2004; 49 (10): 711.

Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. International Clinical Psychopharmacology 2003; 18 (3):121-32.

Potvin S, Stip E, Roy JY. Schizophrenia and addiction: an evaluation of the self-medication hypothesis (french). L’Encéphale 2003 ; XXIX : 193-203.

Chapters

Potvin S, Bauco P, Mancini-Marië A, Roy JY, Rompré PP. (2005) La toxicomanie: aspects fondamentaux et cliniques. Dans: Marquard-Botez T (éd.) Neuropsychologie Clinique et Neurologie du Comportement -3ème édition. Presses de l’Université de Montréal; pp. 635-645.

Potvin S, Stip E, Roy JY. (2005) Hedonic dysfunctions in schizophrenia: l’ennui à la folie. Dans: Lang MV (ed.) Trends in Schizophrenia Research. New York: Nova Science Publishers; pp. 119-149.

Potvin S, Stip E, Roy JY. Schizophrénie et cannabinoïdes: données cliniques, expérimentales et biologiques. Drogues, Santé & Société 2004; 2 (2): 61-97.

Potvin S, Benzaliouad F, Rompré PP. La toxicomanie: les drogues d’abus. Dans: Beaulieu P (éd.) Précis de Pharmacologie. Montréal: Presses de l’Université de Montréal. 2009.

Potvin S, Mancini-Marïe A, Fahim C, Stip E. Les anomalies de la matière grise et la matière blanche dans la schizophrénie: une approche confirmatoire. Dans: Stip É (éd.) ACFAS. Sur invitation.